Drug-Resistant Bacteria on Poultry Products Differ by Brand

The presence of drug-resistant, pathogenic bacteria on uncooked poultry products varies by commercial brand and is likely related to antibiotic use in production, according to researchers at the Johns Hopkins Bloomberg School of Public Health. Their study is the first to directly compare bacterial contamination of poultry products sold in U.S. supermarkets from food producers who use antibiotics and from those who claim they do not. The study focused on antibiotic resistance, specifically fluoroquinolone-resistance in Campylobacter, a pathogen responsible for 2.4 million cases of food-borne illness per year in the U.S., according to the Centers for Disease Control and Prevention. The study is published online in the journal Environmental Health Perspectives.

“Our use of medically important classes of antibiotics in food-animal production creates a significant public health concern,” said the study’s lead author Lance Price, a doctoral candidate and fellow at the Bloomberg School of Public Health’s Center for a Livable Future. “Companies that use antibiotics foster the development of drug-resistant bacteria which can spread to the human population. Claims have been made that using antibiotics increases food safety by reducing pathogens on the meat. Interestingly, in addition to the results regarding fluoroquinolone-resistant Campylobacter, we also found that brands that do not use any antibiotics during production were no more likely to contain Campylobacter than those that do. In fact, the only brand with a significantly lower rate of Campylobacter contamination was actually an antibiotic-free brand.”

Price explained that previous epidemiological studies have indicated that fresh poultry products are a major source of Campylobacter infections in humans. Exposure can occur from undercooked products or through cross-contamination during food preparation, when raw poultry is handled in the kitchen. The danger of infection is heightened when this pathogen is resistant to antibiotics. Not only can the bacteria itself cause illnesses such as diarrhea in humans, but fluoroquinolones are some of the most important drugs used to treat a variety of infections, including those caused by Campylobacter. The widespread presence of this drug-resistant form of the bacteria makes the antibiotic less effective in human medicine. Especially vulnerable are the very young, the elderly and people whose immune systems are compromised.

In 2000, the Food and Drug Administration proposed to withdraw approval of fluoroquinolone drugs for use in poultry production. That effort has since been stalled by legal objections from Bayer, one of the pharmaceutical companies manufacturing the drug. In the meantime, two major U.S. poultry producers, Tyson Food and Perdue Farms, separately announced in 2002 that they would immediately stop using fluoroquinolones to treat poultry flocks.

One year after the Tyson and Perdue announcements, Price and his team began a survey of Campylobacter isolates on uncooked chicken products from Tyson and Perdue and from two other producers, Eberly and Bell & Evans, who claim their production methods are completely antibiotic-free. Using both standard isolation methods and new methods modified to enhance detection of fluoroquinolone-resistant Campylobacter, they compared retail products purchased at grocery stores in Baltimore, Md. A high percentage of the products from the two conventional brands were contaminated with fluoroquinolone-resistant Campylobacter (96 percent from Tyson and 43 percent from Perdue) while significantly lower proportions of ‘antibiotic-free’ products were contaminated with fluoroquinolone-resistant Campylobacter (5 percent from Eberly and 13 percent from Bell & Evans).

“These results suggest that fluoroquinolone-resistance may persist in the food supply for a substantial period of time even after antibiotic use is discontinued,” said Price. “Assuming that what we are observing are lingering resistant strains rather than the result of continued drug use, then one has to conclude that fluoroquinolone use in poultry production presents a long-term threat to people.”

The study was supported by the Johns Hopkins Center for a Livable Future and by the Heinz Family Foundation.

E. Johnson, R. Vailes, and E. Silbergeld from the Johns Hopkins Bloomberg School of Public Health, co-authored this study “Fluoroquinolone-Resistant Campylobacter Isolates from Conventional and Antibiotic-free Chicken Products.”

Public Affairs contact for the Johns Hopkins Center for a Livable Future: Donna Mennito at 410-502-7578 or dmennit@jhsph.edu.

Public Affairs media contacts for the Johns Hopkins Bloomberg School of Public Health: Tim Parsons or Kenna Lowe at 410-955-6878 or paffairs@jhsph.edu.